Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical is a global healthcare company with its dominant political signal being $71.6M in annual payments to U.S. doctors and teaching hospitals.
BusinessWhat TAK does
Takeda Pharmaceutical Company Limited is a global, research-based pharmaceutical company with a primary focus on oncology, rare diseases, neuroscience, gastroenterology, and plasma-derived therapies. Its revenue is generated from the development and commercialization of prescription medicines and vaccines. The company operates a significant U.S. commercial business through its subsidiary, Takeda Pharmaceuticals U.S.A., Inc.
12 months past · 3 months futureTAK activity timeline
Lifetime Government AwardsTAK federal contracts
TAK doesn't hold direct federal contracts.
Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.
Smart Money · 13F HoldingsHedge funds holding TAK
Congressional TradesWho in Congress is trading TAK
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
No Form 4 activity recorded in the last 180 days.
Bills Affecting TAKLive legislation impacting this stock
Political ProfileWhere TAK sits in Washington
[object Object]
STRUCTURAL: High regulatory density from healthcare sector legislation (8 bills with impact_ratio 0.0001) and significant Sunshine Act reporting exposure ($71.6M in 2024 doctor payments). EVIDENTIARY: No evidentiary signals present; zero federal contracts (`get_government_precedent.federal_contracts_summary` is null), zero lobbying spend, zero insider buys (`get_corporate_insider_signal.total_buys` is 0), and zero congressional trades. Net: Structural regulatory risk is not offset by any positive evidentiary alignment.
Regulatory ExposureThreats & opportunities
Regulatory threats
-
Heightened scrutiny of physician payments under the Sunshine ActCenters for Medicare & Medicaid Services (CMS)"`get_political_influence.doctor_payments` shows $71.6M in 2024 payments, creating regulatory and reputational exposure."
Regulatory opportunities
- No specific regulatory opportunities flagged.
Live signals + predictions for TAK — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades TAK
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord